(MedPage Today) — The comeback story of belantamab mafodotin (Blenrep) hit a roadblock Thursday as the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted that the drug does not have a favorable benefit-risk profile in combination with either…
Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/116562
Author :
Publish date : 2025-07-17 21:01:00
Copyright for syndicated content belongs to the linked Source.
